Urologic Neoplasms
📧 Sign up to get email alerts when something new happens for Urologic Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-29EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
EMA authorizes Padcev (enfortumab vedotin) for specified urologic carcinoma indications, marking an official market approval.
-
EMA approval · 2026-07-22EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
The EMA authorised Padcev (enfortumab vedotin) for indicated urologic cancers, marking a new approval by Astellas Pharma Europe B.V.
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-28EMA Authorised: Balversa (Erdafitinib) — Janssen-Cilag International N.V.
Authorised status for Balversa (Erdafitinib) by EMA for urologic neoplasms.
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients
A clinical trial evaluating skin conductance as a predictor of spinal anesthesia-induced hypotension in elderly patients with urologic neopl…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
A clinical trial update examines the significance of adherent perinephric fat for patients undergoing partial nephrectomy, with the study cu…
-
EMA withdrawal · 2021-10-20EMA Application withdrawn: Oportuzumab monatox DLRC Pharma Services (oportuzumab monatox) — DLRC Pharma Services Ltd
The EMA has withdrawn the application for oportuzumab monatox, submitted by DLRC Pharma Services Ltd, for urologic and urinary bladder neopl…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) [Phase 1, Phase 2]
Clinical trial update on tislelizumab in combination with BCG for high-risk non-muscle invasive bladder cancer (HR-NMIBC) across Phase 1 and…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating an individualized treatment strategy for patients with metastatic non-clear cell renal cell carcinoma is ongoing, s…
-
CLINICAL_TRIALS withdrawal · 2015-04-01Clinical Trial Update: SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I [Phase 3]
Phase 3 trial SHTC EUROPE-1 evaluating Synergo hyperthermia-chemotherapy for urinary bladder neoplasms has been withdrawn.
-
CLINICAL_TRIALS research · 2008-03-04Clinical Trial Update: Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
A clinical trial update describing the collection of genetic samples for analysis of inherited urologic cancer syndromes.